FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

Greetings and welcome to the X4 Pharmaceuticals fourth quarter and full year 2024 financial and operating results conference call. (Operator Instructions) and it is now my pleasure to turn to your ...

WASHINGTON, DC – The U.S. Department of Justice has charged Indian chemical manufacturer Vasudha Pharma Chem Limited (VPC) ...

Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.

As Robert F. Kennedy Jr. settles into his role as President Donald Trump’s health secretary, one major promise he’s made is ...

The PMCPA has dug into the industry’s LinkedIn activities once again. | The PMCPA has dug into the industry’s LinkedIn ...

For some Big Pharma companies, sales in China contributed to more than 10 percent of global sales, making China a top market ...

In this episode of The Top Line, sponsored by PatientPoint, Andrew Schultz, President of PatientPoint Precision, discusses ...

Resmetirom is a medication approved by the FDA to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with ...

Esteve Química, the CDMO division of leading specialty pharmaceutical company ESTEVE, has been named the Champion of the 2025 CDMO Leadership Award in the Small Molecule API – Global Category. This ...

Highlighting deals by PE firms pursuing investments in marketing agencies focused on pharma and life sciences; insights on a ...

PE Hub rounded up five pharma marketing deals from the last five months, starting with the most recently announced. (We have ...